Daxotel Docetaxel 80mg Injection
SKU: MB-1370AnticancerInjectables

Daxotel Docetaxel 80mg Injection

Save

Docetaxel 80 mg Injection

Docetaxel 80 mg Injection treats breast cancer, non-small cell lung cancer, prostate cancer, head and neck cancer.

Quick Connect Inquiry:

Technical Specifications

Drug CompositionDocetaxel 80 mg Injection
Variant / Strength80 mg
Dosage Form / TypeInjectables
Product BenefitsCancer of Breast, head and neck., non-small cell lung, prostate
Packaging TypeVial
Delivery Time7 - 15 Days, as per delivery location.
Country of OriginMade in India
Export DestinationsUSA, UK, UAE, Philippines, Thailand, Kenya, Nigeria, Germany, Canada, Mexico, and 65+ more countries
Export RouteShipped via temperature-controlled international air courier with full customs documentation
Product Overview & Descriptionβ–²

Docetaxel Injection is an anti-cancer medication prescribed for breast cancer, non-small cell lung cancer, prostate cancer, and head and neck cancers. Administered as an injection by a qualified medical professional, the dosage and frequency are determined by the treating doctor, emphasizing precise adherence to avoid serious side effects. The onset of benefits may require several weeks or months, and discontinuation should only occur under the guidance of the doctor.

Submit Quotation Requestβ–Ό
Verified Customer Reviews (0)β–Ό
Frequently Asked Questionsβ–Ό
ℹ️ Information reviewed by Medibliss Lifesciences Editorial Team. Last reviewed: August 2026. Data sourced from manufacturer documentation and WHO-GMP certificates.
Disclaimer: The information provided on this page is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Medibliss Lifesciences acts solely as an exporter and supplier. Please consult your physician or a qualified healthcare provider before starting any medication. We do not manufacture these products and rely on the manufacturer's provided documentation and WHO-GMP certifications for product information.